39 Results for "

Bone morphogenetic proteins

" in MedChemExpress (MCE) Product Catalog:
Products (39)

39 Results for "Bone morphogenetic proteins" in MCE Product Catalog:

93
93 Publications Verification
Cat. No.: HY-12071
CAS No.: 1062368-24-4
Purity:  99.41%
Synonyms: DM-3189
Research Areas:  

Cancer

LDN193189 (DM-3189) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .
loading...
    loading...
93
93 Publications Verification
Cat. No.: HY-12071B
CAS No.: 1435934-00-1
Purity:  99.75%
Synonyms: DM-3189 dihydrochloride
Research Areas:  

Cancer

LDN193189 (DM-3189) dihydrochloride is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .
loading...
    loading...
93
93 Publications Verification
Cat. No.: HY-12071A
CAS No.: 2310134-98-4
Purity:  99.79%
Synonyms: DM-3189 Tetrahydrochloride
Research Areas:  

Cancer

LDN193189 (DM-3189) Tetrahydrochloride is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .
loading...
    loading...
81
81 Cited Publications
Cat. No.: HY-12071C
CAS No.: 1062368-62-0
Synonyms: DM-3189 hydrochloride
LDN193189 (DM-3189) hydrochloride is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-124697
CAS No.: 100874-08-6
Purity:  99.98%
Target:  

TGF-β Receptor

Research Areas:  

Cancer

BMP signaling agonist sb4 is a potent benzoxazole bone morphogenetic protein 4 (BMP4) signaling agonist with a EC50 value of 74 nM, activates BMP signaling by stabilizing intracellular p-SMAD-1/5/9. BMP signaling agonist sb4 activates BMP4 target genes (inhibitors of DNA binding,?Id1?and?Id3) canonical BMP signaling .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-12278
CAS No.: 1431985-92-0
Purity:  99.65%
Target:  

TGF-β Receptor

Research Areas:  

Others

K02288 is a potent bone morphogenetic protein (BMP) type I receptor inhibitor with IC50s of 1.8, 1.1, 6.4 nM for ALK1, ALK2 and ALK6, respectively. K02288 shows slightly weaker inhibition against ALK3 and ALK6 with IC50s of of 5-34 nM.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N0316
CAS No.: 55481-88-4
Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-112331
CAS No.: 425613-09-8
Purity:  99.66%
Target:  

TGF-β Receptor

Research Areas:  

Cancer

SJ000291942 is an activator of the canonical bone morphogenetic proteins (BMP) signaling pathway. BMPs are members of the transforming growth factor beta (TGFβ) family of secreted signaling molecules.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16712
CAS No.: 1627503-67-6
Target:  

TGF-β Receptor

Research Areas:  

Cancer

LDN-214117 is an orally active ALK2 inhibitor with well-tolerated and good brain penetration. LDN-214117 has a high selectivity and low cytotoxicity for ALK2 with an IC50 value of 24 nM. LDN-214117 also is a specific bone morphogenetic proteins (BMPs) signaling inhibitor and has relatively selective inhibition for BMP6 with an IC50 value of 100 nM. LDN-214117 can be used for the research of fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma (DIPG) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15897
CAS No.: 1432597-26-6
Purity:  99.70%
Target:  

TGF-β Receptor

Research Areas:  

Cancer

LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM). LDN-212854 also inhibits ALK1 (IC50: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-76520
CAS No.: 184036-34-8
Synonyms: IPI 1040; TBC-11251
Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P10710A
BMP-4 (15-24) acetate is a cell-penetrating heparin-binding peptide with the sequence RKKNPNCRRH. BMP-4 (15-24) acetate exhibits anti-inflammatory and anti-chondrogenic activities. BMP-4 (15-24) acetate can be used in the research of arthritis .
loading...
    loading...
Cat. No.: HY-12071G
CAS No.: 1062368-24-4
Synonyms: DM-3189 (GMP)
LDN193189 GMP is LDN193189 (HY-12071) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LDN193189 (DM-3189) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .
loading...
    loading...
Cat. No.: HY-N6588
CAS No.: 86632-03-3
Synonyms: 3,4,5-triCQA
3,4,5-Tricaffeoylquinic acid (3,4,5-triCQA) inhibits tumor necrosis factor-α-stimulated production of inflammatory mediators in keratinocytes via suppression of Akt- and NF-κB-pathways. 3,4,5-Tricaffeoylquinic acid induces cell cycle arrest at G0/G1, actin cytoskeleton organization, chromatin remodeling, neuronal differentiation, and bone morphogenetic protein signaling in human neural stem cells. 3,4,5-Tricaffeoylquinic acid has the potential for the research of aging-associated diseases .
loading...
    loading...
Cat. No.: HY-150793
CAS No.: 2253719-35-4
Purity:  99.66%
SY-LB-57 is a highly potent bone morphogenetic protein (BMP) receptor signaling agonist. SY-LB-57 can be used in studies of diseases such as fractures and pulmonary arterial hypertension .
loading...
    loading...
Cat. No.: HY-100434
CAS No.: 192705-80-9
Purity:  99.82%
Research Areas:  

Cardiovascular Disease Cancer

PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively. PD-161570 inhibits PDGF-stimulated autophosphorylation and FGF-1 receptor phosphorylation with IC50s of 450 nM and 622 nM, respectively . PD-161570 is also a bone morphogenetic proteins (BMPs) and TGF-β signaling inhibitor .
loading...
    loading...
Cat. No.: HY-150795
CAS No.: 2603461-70-5
Purity:  99.54%
Target:  

TGF-beta/Smad PI3K Akt ERK JNK

Research Areas:  

Others

SY-LB-35 is a potent bone morphogenetic protein (BMP) receptor agonist. SY-LB-35 can stimulate significant increases in cell number and cell viability in the C2C12 myoblast cell line, and causes shifts towards the S and G2/M phases of the cell cycle. SY-LB-35 stimulates canonical Smad and non-canonical PI3K/Akt, ERK, p38 and JNK intracellular signaling pathways .
loading...
    loading...
Cat. No.: HY-P10710
CAS No.: 1629625-47-3
BMP-4 (15-24) is a cell-penetrating heparin-binding peptide with the sequence RKKNPNCRRH. BMP-4 (15-24) exhibits anti-inflammatory and anti-chondrogenic activities. BMP-4 (15-24) can be used in the research of arthritis .
loading...
    loading...
Cat. No.: HY-174416
CAS No.: 1824647-09-7
Target:  

E1/E2/E3 Enzyme

Research Areas:  

Cardiovascular Disease

Smurf1-IN-5 (Compound cpd-6) is an allosteric SMAD ubiquitin regulatory factor 1 (SMURF1) inhibitor. Smurf1-IN-5 leads to a reduction in the ubiquitylation of substrates such as BMPR2 (bone morphogenetic protein receptor 2) and SMAD1, enhancing the BMP (bone morphogenetic protein) signaling pathway. Smurf1-IN-5 is promising for research of pulmonary arterial hypertension (PAH) .
loading...
    loading...
Cat. No.: HY-142042
CAS No.: 287196-91-2
Purity:  99.84%
3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is an inhibitor for bone morphogenetic protein 2 (BMP2) with an IC50 of 2.2 μM. 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is inhibitor for mitogen-activated protein kinase 1 (MEK1). 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles exhibits anti-inflammatory and neuroprotective activity in EAE mouse model .
loading...
    loading...